一种化合物、包含该化合物的螯合物及其应用
By modifying and transforming the structure of cyclic peptide-DOTA conjugates, novel compounds were designed, which solved the problems of low uptake rate, poor binding, and high accumulation in non-target organs of existing cyclic peptide-DOTA conjugates, thus achieving more efficient tumor targeting and therapeutic effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- BOOMRAY PHARMACEUTICALS CO LTD
- Filing Date
- 2026-04-22
- Publication Date
- 2026-07-17
AI Technical Summary
Existing cyclic peptide-DOTA conjugates suffer from insufficient uptake by tumor cells, poor cell binding, inadequate tumor retention time, and high accumulation in non-target organs (especially the kidneys), which limits their therapeutic window and clinical application potential.
By modifying and transforming specific groups of cyclic peptide-DOTA conjugates, a series of novel compounds were designed and their structures were optimized to improve tumor cell uptake and binding, prolong tumor retention time, and reduce accumulation in non-target organs.
In animal models, it showed significantly improved tumor uptake and retention time, reduced accumulation in non-target organs, enhanced therapeutic efficacy and improved safety, and broadened the therapeutic window.
Smart Images
Figure CN122404497A_ABST